These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 37115694)
1. Aspirin and immunotherapy: a Faustian bargain? Goethe EA; Heimberger AB; Rao G J Clin Invest; 2023 May; 133(9):. PubMed ID: 37115694 [TBL] [Abstract][Full Text] [Related]
2. Targeting fibrinogen-like protein 1 enhances immunotherapy in hepatocellular carcinoma. Lin M; He J; Zhang X; Sun X; Dong W; Zhang R; Xu Y; Lv L J Clin Invest; 2023 May; 133(9):. PubMed ID: 37115693 [TBL] [Abstract][Full Text] [Related]
3. The correlation of fibrinogen-like protein-1 expression with the progression and prognosis of hepatocellular carcinoma. Hua N; Chen A; Yang C; Dong H; He X; Ru G; Tong X; Zhou F; Wang S Mol Biol Rep; 2022 Aug; 49(8):7911-7919. PubMed ID: 35776395 [TBL] [Abstract][Full Text] [Related]
4. Fibrinogen-Like Protein 1 Modulates Sorafenib Resistance in Human Hepatocellular Carcinoma Cells. Son Y; Shin NR; Kim SH; Park SC; Lee HJ Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34069373 [TBL] [Abstract][Full Text] [Related]
5. Targeted disruption of fibrinogen like protein-1 accelerates hepatocellular carcinoma development. Nayeb-Hashemi H; Desai A; Demchev V; Bronson RT; Hornick JL; Cohen DE; Ukomadu C Biochem Biophys Res Commun; 2015 Sep; 465(2):167-73. PubMed ID: 26225745 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of Serum FGL1 as Diagnostic Markers for HBV-Related Hepatocellular Carcinoma. Cai X; Tang D; Chen J; Li H; Zhang P Lab Med; 2023 May; 54(3):270-281. PubMed ID: 36219698 [TBL] [Abstract][Full Text] [Related]
7. Fibrinogen-like protein 1 promotes liver-resident memory T-cell exhaustion in hepatocellular carcinoma. Yang C; Qian Q; Zhao Y; Huang B; Chen R; Gong Q; Ji H; Wang C; Xia L; You Z; Zhang J; Chen X Front Immunol; 2023; 14():1112672. PubMed ID: 36993960 [TBL] [Abstract][Full Text] [Related]
8. Expression and clinical significance of LAG-3, FGL1, PD-L1 and CD8 Guo M; Yuan F; Qi F; Sun J; Rao Q; Zhao Z; Huang P; Fang T; Yang B; Xia J J Transl Med; 2020 Aug; 18(1):306. PubMed ID: 32762721 [TBL] [Abstract][Full Text] [Related]
9. Oxysophocarpine suppresses hepatocellular carcinoma growth and sensitizes the therapeutic blockade of anti-Lag-3 via reducing FGL1 expression. Wang J; Wei W; Tang Q; Lu L; Luo Z; Li W; Lu Y; Pu J Cancer Med; 2020 Oct; 9(19):7125-7136. PubMed ID: 32810392 [TBL] [Abstract][Full Text] [Related]
10. FGL1 and FGL2: emerging regulators of liver health and disease. Chen J; Wu L; Li Y Biomark Res; 2024 May; 12(1):53. PubMed ID: 38816776 [TBL] [Abstract][Full Text] [Related]
11. Implication of the hepatokine, fibrinogen-like protein 1 in liver diseases, metabolic disorders and cancer: The need to harness its full potential. Liu XH; Qi LW; Alolga RN; Liu Q Int J Biol Sci; 2022; 18(1):292-300. PubMed ID: 34975333 [TBL] [Abstract][Full Text] [Related]
12. Neurotransmitters and Neuropeptides decrease PD-1 in T cells of healthy subjects and patients with hepatocellular carcinoma (HCC), and increase their proliferation and eradication of HCC cells. Levite M; Safadi R; Milgrom Y; Massarwa M; Galun E Neuropeptides; 2021 Oct; 89():102159. PubMed ID: 34293596 [TBL] [Abstract][Full Text] [Related]
13. The liver microenvironment orchestrates FGL1-mediated immune escape and progression of metastatic colorectal cancer. Li JJ; Wang JH; Tian T; Liu J; Zheng YQ; Mo HY; Sheng H; Chen YX; Wu QN; Han Y; Liao K; Pan YQ; Zeng ZL; Liu ZX; Yang W; Xu RH; Ju HQ Nat Commun; 2023 Oct; 14(1):6690. PubMed ID: 37872170 [TBL] [Abstract][Full Text] [Related]
14. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma. Luo Y; Liu H; Fu H; Ding GS; Teng F Front Immunol; 2022; 13():974377. PubMed ID: 36458010 [TBL] [Abstract][Full Text] [Related]
15. Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3. Wang J; Sanmamed MF; Datar I; Su TT; Ji L; Sun J; Chen L; Chen Y; Zhu G; Yin W; Zheng L; Zhou T; Badri T; Yao S; Zhu S; Boto A; Sznol M; Melero I; Vignali DAA; Schalper K; Chen L Cell; 2019 Jan; 176(1-2):334-347.e12. PubMed ID: 30580966 [TBL] [Abstract][Full Text] [Related]
16. Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target. Qian W; Zhao M; Wang R; Li H J Hematol Oncol; 2021 Sep; 14(1):147. PubMed ID: 34526102 [TBL] [Abstract][Full Text] [Related]
17. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas. Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905 [TBL] [Abstract][Full Text] [Related]
18. Aspirin targets P4HA2 through inhibiting NF-κB and LMCD1-AS1/let-7g to inhibit tumour growth and collagen deposition in hepatocellular carcinoma. Wang T; Fu X; Jin T; Zhang L; Liu B; Wu Y; Xu F; Wang X; Ye K; Zhang W; Ye L EBioMedicine; 2019 Jul; 45():168-180. PubMed ID: 31278071 [TBL] [Abstract][Full Text] [Related]
19. Statin and aspirin for chemoprevention of hepatocellular carcinoma: Time to use or wait further? Goh MJ; Sinn DH Clin Mol Hepatol; 2022 Jul; 28(3):380-395. PubMed ID: 35021597 [TBL] [Abstract][Full Text] [Related]
20. Aspirin in Hepatocellular Carcinoma. Ricciotti E; Wangensteen KJ; FitzGerald GA Cancer Res; 2021 Jul; 81(14):3751-3761. PubMed ID: 33893087 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]